Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Medicare coverage for biologic therapies -- a mainstay of treatment for rheumatoid arthritis-- has been in flux recently. Medicare Part B coverage for biologic therapy ended in 2004, and the Medicare ...

Overall, the “Hidradenitis Suppuritiva Update 2026” session underscored a new treatment paradigm: HS care in 2026 requires early diagnosis, systemic screening, combination medical therapy, and ...

In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

Please provide your email address to receive an email when new articles are posted on . Less than 15% of PCPs reported managing patients with uncontrolled asthma at least once a week. More PCPs ...

It is the first clinical trial to evaluate a biologic therapy to prevent serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 ...

The use of biologics is rapidly increasing as new drugs are approved for label expansions. Monoclonal antibodies, multispecific antibodies, and antibody-drug conjugates (ADCs) are being implemented in ...

Please provide your email address to receive an email when new articles are posted on . Biologic therapies are underutilized in non-white populations. By identifying barriers to specific biologic ...

A high quantity of opioid medication among individuals hospitalized with acute severe ulcerative colitis is linked to a delay in administration of biologic rescue therapy. High opioid use during acute ...

Biologic Therapies has announced it has received FDA clearance for its new bone marrow aspiration catheter, according to a news release. The Bio-MAC bone marrow aspiration catheter is designed to ...

Whereas natural tolerance rates are generally high for common allergens, such as eggs, milk, and wheat, allergies to other foods often persist beyond childhood. For instance, approximately 72.2% of ...

Access to biologic therapy, such as omalizumab, is a significant barrier for CSU patients in Latin America, despite high disease knowledge. Participants in the pilot program had high baseline ...